A crucial question is whether it is better to develop broad-spectrum modulators able to target multiple protein precursors, e.g. Aβ and α-Syn, Aβ and Tau or Aβ and hIAPP (in LB, AD and T2D, respectively), rather than hunting for small molecules with high specificity. This evidence concerns the gene MAPT and Alzheimer disease.